Expression of the RANK/RANKL/OPG system in the human intervertebral disc: implication for the pathogenesis of intervertebral disc degeneration

1. Kepler CK, Ponnappan RK, Tannoury CA, Risbud MV, Anderson DG. The

molecular basis of intervertebral disc degeneration. Spine J. 2013;13(3):

318–30.

2. Millward-Sadler SJ, Costello PW, Freemont AJ, Hoyland JA. Regulation of

catabolic gene expression in normal and degenerate human intervertebral

disc cells: implications for the pathogenesis of intervertebral disc

degeneration. Arthritis Res Ther. 2009;11(3):R65.

3. Zhao CQ, Liu D, Li H, Jiang LS, Dai LY. Interleukin-1beta enhances the effect

of serum deprivation on rat annular cell apoptosis. Apoptosis. 2007;12(12):

2155–61.

4. Vo NV, Hartman RA, Patil PR, Risbud MV, Kletsas D, Iatridis JC, et al.

Molecular mechanisms of biological aging in intervertebral discs. J Orthop

Res. 2016;34(8):1289–306.

5. Le Maitre CL, Freemont AJ, Hoyland JA. The role of interleukin-1 in the

pathogenesis of human intervertebral disc degeneration. Arthritis Res Ther.

2005;7(4):R732–45.

6. Le Maitre CL, Hoyland JA, Freemont AJ. Catabolic cytokine expression in

degenerate and herniated human intervertebral discs: IL-1beta and

TNFalpha expression profile. Arthritis Res Ther. 2007;9(4):R77.

7. Cabal-Hierro L, Lazo PS. Signal transduction by tumor necrosis factor

receptors. Cell Signal. 2012;24(6):1297–305.

8. Johnson ZI, Schoepflin ZR, Choi H, Shapiro IM, Risbud MV. Disc in flames:

roles of TNF-alpha and IL-1beta in intervertebral disc degeneration. Eur Cell

Mater 2015;30:104–116; discussion 16-7.

9. Garcia-Cosamalon J, del Valle ME, Calavia MG, Garcia-Suarez O, Lopez-Muniz

A, Otero J, et al. Intervertebral disc, sensory nerves and neurotrophins: who

is who in discogenic pain? J Anat. 2010;217(1):1–15.

Sano et al. BMC Musculoskeletal Disorders

(2019) 20:225

10. Luoma K, Vehmas T, Raininko R, Luukkonen R, Riihimaki H. Lumbosacral

transitional vertebra: relation to disc degeneration and low back pain. Spine

(Phila Pa 1976). 2004;29(2):200–5.

11. Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME,

Roux ER, et al. A homologue of the TNF receptor and its ligand

enhance T-cell growth and dendritic-cell function. Nature. 1997;

390(6656):175–9.

12. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation.

Nature. 2003;423(6937):337–42.

13. Komuro H, Olee T, Kuhn K, Quach J, Brinson DC, Shikhman A, et al. The

osteoprotegerin/receptor activator of nuclear factor kappaB/receptor

activator of nuclear factor kappaB ligand system in cartilage. Arthritis

Rheum. 2001;44(12):2768–76.

14. Kwan Tat S, Amiable N, Pelletier JP, Boileau C, Lajeunesse D, Duval N, et al.

Modulation of OPG, RANK and RANKL by human chondrocytes and their

implication during osteoarthritis. Rheumatology (Oxford). 2009;48(12):1482–90.

15. Gruber HE, Ingram JA, Hoelscher GL, Zinchenko N, Norton HJ, Hanley EN, Jr.

Constitutive expression of cathepsin K in the human intervertebral disc:

new insight into disc extracellular matrix remodeling via cathepsin K and

receptor activator of nuclear factor-kappaB ligand. Arthritis Res Ther 2011;

13(4):R140.

16. Mackiewicz Z, Salo J, Konttinen YT, Kaigle Holm A, Indahl A, Pajarinen J, et

al. Receptor activator of nuclear factor kappa B ligand in an experimental

intervertebral disc degeneration. Clin Exp Rheumatol. 2009;27(2):299–306.

17. Rutges JP, Duit RA, Kummer JA, Oner FC, van Rijen MH, Verbout AJ, et al.

Hypertrophic differentiation and calcification during intervertebral disc

degeneration. Osteoarthr Cartil. 2010;18(11):1487–95.

18. Takegami N, Akeda K, Yamada J, Sano T, Murata K, Huang J, et al. RANK/

RANKL/OPG system in the intervertebral disc. Arthritis Res Ther. 2017;19(1):121.

19. Roughley PJ. Biology of intervertebral disc aging and degeneration: involvement

of the extracellular matrix. Spine (Phila Pa 1976). 2004;29(23):2691–9.

20. Byron CR, Barger AM, Stewart AA, Pondenis HC, Fan TM. In vitro expression

of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in

cultured equine articular cells. Am J Vet Res. 2010;71(6):615–22.

21. Gravallese EM, Manning C, Tsay A, Naito A, Pan C, Amento E, et al. Synovial

tissue in rheumatoid arthritis is a source of osteoclast differentiation factor.

Arthritis Rheum. 2000;43(2):250–8.

22. Mladenovic Z, Saurel AS, Berenbaum F, Jacques C. Potential role of

hyaluronic acid on bone in osteoarthritis: matrix metalloproteinases,

aggrecanases, and RANKL expression are partially prevented by hyaluronic

acid in interleukin 1-stimulated osteoblasts. J Rheumatol. 2014;41(5):945–54.

23. Takayanagi H. Osteoimmunology: shared mechanisms and crosstalk between the

immune and bone systems. Nat Rev Immunol. 2007;7(4):292–304.

24. Steeve KT, Marc P, Sandrine T, Dominique H, Yannick F. IL-6, RANKL, TNFalpha/IL-1: interrelations in bone resorption pathophysiology. Cytokine

Growth Factor Rev. 2004;15(1):49–60.

25. Papanastasiou AD, Sirinian C, Kalofonos HP. Identification of novel human

receptor activator of nuclear factor-kB isoforms generated through

alternative splicing: implications in breast cancer cell survival and migration.

Breast Cancer Res. 2012;14(4):R112.

26. Sirinian C, Papanastasiou AD, Zarkadis IK, Kalofonos HP. Alternative splicing

generates a truncated isoform of human TNFRSF11A (RANK) with an altered

capacity to activate NF-kappaB. Gene. 2013;525(1):124–9.

27. Kadri A, Ea HK, Bazille C, Hannouche D, Liote F, Cohen-Solal ME.

Osteoprotegerin inhibits cartilage degradation through an effect on

trabecular bone in murine experimental osteoarthritis. Arthritis Rheum.

2008;58(8):2379–86.

28. Shimizu S, Asou Y, Itoh S, Chung UI, Kawaguchi H, Shinomiya K, et al.

Prevention of cartilage destruction with intraarticular osteoclastogenesis

inhibitory factor/osteoprotegerin in a murine model of osteoarthritis.

Arthritis Rheum. 2007;56(10):3358–65.

29. Bone HG, Bolognese MA, Yuen CK, Kendler DL, Wang H, Liu Y, et al. Effects

of denosumab on bone mineral density and bone turnover in

postmenopausal women. J Clin Endocrinol Metab. 2008;93(6):2149–57.

30. Cohen SB, Dore RK, Lane NE, Ory PA, Peterfy CG, Sharp JT, et al. Denosumab

treatment effects on structural damage, bone mineral density, and bone

turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized,

double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum. 2008;

58(5):1299–309.

31. Deodhar A, Dore RK, Mandel D, Schechtman J, Shergy W, Trapp R, et al.

Denosumab-mediated increase in hand bone mineral density associated

Page 13 of 13

32.

33.

34.

35.

36.

37.

38.

39.

40.

with decreased progression of bone erosion in rheumatoid arthritis patients.

Arthritis Care Res (Hoboken). 2010;62(4):569–74.

Atkinson SM, Bleil J, Maier R, Kuhl AA, Thorn M, Serikawa K, et al. Anti-RANKL

treatment inhibits erosive joint destruction and lowers inflammation but

has no effect on bone formation in the delayed-type hypersensitivity

arthritis (DTHA) model. Arthritis Res Ther. 2016;18:28.

Sato M, Inage K, Sakuma Y, Sato J, Orita S, Yamauchi K, et al. Anti-RANKL

antibodies decrease CGRP expression in dorsal root ganglion neurons

innervating injured lumbar intervertebral discs in rats. Eur Spine J. 2015;

24(9):2017–22.

Neogi T, Nevitt MC, Ensrud KE, Bauer D, Felson DT. The effect of

alendronate on progression of spinal osteophytes and disc-space

narrowing. Ann Rheum Dis. 2008;67(10):1427–30.

Luo Y, Zhang L, Wang WY, Hu QF, Song HP, Su YL, et al. Alendronate

retards the progression of lumbar intervertebral disc degeneration in

ovariectomized rats. Bone. 2013;55(2):439–48.

Song H, Luo Y, Wang W, Li S, Yang K, Dai M, et al. Effects of alendronate on

lumbar intervertebral disc degeneration with bone loss in ovariectomized

rats. Spine J. 2017;17(7):995–1003.

Patel D, Madani S, Patel S, Guglani L. Review of pulmonary adverse effects

of infliximab therapy in Crohn's disease. Expert Opin Drug Saf. 2016;15(6):

769–75.

Xue JB, Zhan XL, Wang WJ, Yan YG, Liu C. OPG rs2073617 polymorphism is

associated with upregulated OPG protein expression and an increased risk

of intervertebral disc degeneration. Exp Ther Med. 2016;12(2):702–10.

Jonsson B, Strom O, Eisman JA, Papaioannou A, Siris ES, Tosteson A, et al.

Cost-effectiveness of Denosumab for the treatment of postmenopausal

osteoporosis. Osteoporos Int. 2011;22(3):967–82.

Silverman S, Agodoa I, Kruse M, Parthan A, Orwoll E. Denosumab for elderly

men with osteoporosis: a cost-effectiveness analysis from the US payer

perspective. J Osteoporos 2015;2015:627631.

Readytosubmityourresearch? ChooseBMCandb

tfrom:

• f

,convenientonl

esubmission

• thoroughpeerreviewbyexperiencedr

si

nyourf

• r

dp

nonacceptance

• supportf

rr

hd

,i

gl

eandcomplexdatat

• g

dOpenAccesswhichf

swiderc

nandi

dc

• maximumv

yf

ryourr

:overlOOMwebsiteviewsperyear

AtBMC,r

hi

salwaysi

np

Learnmorebiomedcentral.com/submissions

BMC

...